Sign In

Mark Engel

Chairman at Precisio Biotix Therapeutics

Mark Engel is an experienced entrepreneur and executive in the life sciences industry, with a focus on biotechnology and pharmaceuticals. He is currently the Chairman and CEO of Precisio Biotix Therapeutics, a company developing biological antibacterials.12

Career Highlights

Precisio Biotix and Subsidiaries::

  • Founder of Phagelux, a subsidiary of Precisio Biotix, which creates phage-based topical solutions for antimicrobial-resistant skin conditions.1
  • CEO of Phagelux, Inc., which recently changed the name of its Wuhan-based subsidiary to Lysigen.3

Other Current Roles::

  • Chairman of Phagelux AgriHealth, developing phage-based solutions for crop sciences, food safety, and animal health.1
  • Managing Director of Tianshi Capital, an early-stage investor in life sciences.12
  • Director at Haoyisheng.com, a leading healthcare technology company in China.1

Entrepreneurial Background

Mark Engel has a track record of founding and building successful life sciences companies since 1990, particularly in China. Some of his previous ventures include:

  • NPO Pharmaceutical (sold)
  • Excel PharmaStudies (sold to PPD in 2009)
  • Tiger Medical Group (sold)
  • Haoyisheng ("Good Doctor")2

Expertise

Engel has rich experience in new drug registrations and product commercialization. His focus at Precisio Biotix and its subsidiaries is on developing biological antibacterials, with an emphasis on topical treatments for difficult-to-treat diseases.12

Education

While not explicitly stated in the provided search results, Engel's LinkedIn profile indicates he has a background in business and marketing, with experience at companies like General Mills and SC Johnson earlier in his career.4

Highlights

Aug 26 · linkedin

Nanjing, China: As Phagelux grows globally, we increasingly invest more resources into R&D. At our new facility in Nanjing, China we are investing into creating novel bio-products for China and South East Asia. Our products are environmentally friendly (i.e., replace antibiotics and heavy metals) and are used to improve animal health, food safety and crop sciences. In addition to treatments and preventions, the products often also increase yields. Great products; great science; great team! Stay tuned for more expansion news!

Aug 7 · linkedin

Nanjing, China: This weekend the Phagelux AgriHealth China R&D team will move to our new R&D facility in Nanjing, China. This is another positive sign that markets across the globe are increasingly accepting our phage products for animal health, crop sciences and food safety. These products are replacing heavy chemicals and antibiotics and doing so in an environmentally friendly and cost effective way - and often with increased outputs/yields!

Related Questions

What are the main projects Mark Engel is currently working on at Lysigen?
How did Mark Engel transition from founding Tiger Medical Group to becoming CEO of Precisio Biotix?
What makes Lysigen's approach to antibiotic resistance unique compared to traditional methods?
Can you provide more details on the LysiThru system developed by Lysigen?
What are the key achievements of Mark Engel in the life sciences industry?
Mark Engel
Mark Engel, photo 1
Mark Engel, photo 2
Add to my network

Location

United States